Yin, Lin, Cai, Nie and colleagues report phase separation of ERCC6L2 as a mechanism that regulates RNF138-mediated ubiquitination and degradation of CtIP, thereby modulating DNA end resection and treatment response to ATM inhibitors in cancer.